Long-term safety and efficacy of the novel β3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study
Open Access
- 1 July 2018
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 25 (7), 668-675
- https://doi.org/10.1111/iju.13596
Abstract
ObjectivesTo evaluate the long-term safety and efficacy of vibegron 50mg and 100mg, a novel (3)-adrenoreceptor agonist, in Japanese patients with overactive bladder. MethodsThis was a 1-year, multicenter, open-label, non-controlled study. After a 1-week observation phase, patients were treated with vibegron for 52weeks. When the efficacy was insufficient after an 8-week treatment with 50mg, the dose was increased to 100mg and maintained for an additional 44weeks. ResultsAmong a total of 169 patients receiving one or more doses of vibegron, 118 (69.8%) received vibegron 50mg for 52weeks, and the dose was increased to 100mg in 51 (30.2%) patients. The incidence of drug-related adverse events was 18.1% (21/116) in the vibegron 50mg group and 11.8% (6/51) in the vibegron 100mg group. Most frequent drug-related adverse events were dry mouth (3.0%), residual urine volume increased (3.0%), constipation (2.4%) and cystitis (1.8%). Statistically significant changes in overactive bladder symptom variables (daily means of micturitions, urgency episodes, urgency incontinence episodes, incontinence episodes and night-time frequency) from baseline were observed at week4 and maintained until week52. The condition of patients who did not respond well to vibegron 50mg was much improved by increasing the dose to 100mg. Vibegron improved the quality of life, and the proportion of patients' satisfaction after the treatment with vibegron was high. ConclusionsLong-term (52-week) treatment with vibegron is safe, well-tolerated and effective in patients with overactive bladder.Keywords
This publication has 23 references indexed in Scilit:
- Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic reviewHealth and Quality of Life Outcomes, 2013
- The placebo effect in overactive bladder syndromeNature Reviews Urology, 2011
- Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literatureInternational Journal of Clinical Practice, 2011
- Muscarinic receptor antagonists for overactive bladderBJU International, 2007
- Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC StudyEuropean Urology, 2006
- An epidemiological survey of overactive bladder symptoms in JapanBJU International, 2005
- Reliability and validity of King's Health Questionnaire in patients with symptoms of overactive bladder with urge incontinence in JapanNeurourology and Urodynamics, 2004
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- EXPRESSION AND POSSIBLE FUNCTIONAL ROLE OF THE beta 3-ADRENOCEPTOR IN HUMAN AND RAT DETRUSOR MUSCLEJournal of Urology, 1999
- Functional and molecular biological evidence for a possible β3‐adrenoceptor in the human detrusor muscleBritish Journal of Pharmacology, 1999